What the database contains
This database includes 120+ new drug candidates in China, from preclinical to phase III clinical studies. All of the candidates in the database include the following information:
ú  Name of developer
ú  Phase of development
ú  Indication

More than 30% of the candidates have the following included information
ú  Additional information : target, similar drugs, mechanism of action
ú  Patent status
ú  Patent number

Method of information collection
For most of the candidates within this database, information is not available or easily accessible in the public domain. This information is compiled through a multi step process. Resources such as patent databases, funding databases, scholarly papers, conference presentations, technology transfer offices of universities and institutes, industry participants, and websites are accessed. In addition, direct contact with an individual involved with each candidate is established to confirm the accuracy of the information and to add further detail.

Why you should purchase report/database
China's innovative science, while facing many obstacles, continues to gather momentum. New drug candidates have been discovered in China and are being developed. Overseas Chinese are also brining back technologies and ideas for development in China. With the competition for compounds at fever pitch in developed markets, big pharma, biotechnology companies and investors should seek out China's opportunities. This database and corresponding report helps to erase the considerable information asymmetries that exist in China.